CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas

Arnaud Bakaric,Luisa Cironi,Viviane Praz,Rajendran Sanalkumar,Liliane C. Broye,Kerria Favre-Bulle,Igor Letovanec,Antonia Digklia,Raffaele Renella,Ivan Stamenkovic,Christopher J. Ott,Takuro Nakamura,Cristina R. Antonescu,Miguel N. Rivera,Nicolò Riggi

DOI: https://doi.org/10.3390/cancers16020457

2024-01-22

Cancers

Abstract:CIC-DUX4-rearranged sarcoma (CDS) is a rare and aggressive soft tissue tumor that occurs most frequently in young adults. The key oncogenic driver of this disease is the expression of the CIC-DUX4 fusion protein as a result of chromosomal rearrangements. CIC-DUX4 displays chromatin binding properties, and is therefore believed to function as an aberrant transcription factor. However, the chromatin remodeling events induced by CIC-DUX4 are not well understood, limiting our ability to identify new mechanism-based therapeutic strategies for these patients. Here, we generated a genome-wide profile of CIC-DUX4 DNA occupancy and associated chromatin states in human CDS cell models and primary tumors. Combining chromatin profiling, proximity ligation assays, as well as genetic and pharmacological perturbations, we show that CIC-DUX4 operates as a potent transcriptional activator at its binding sites. This property is in contrast with the repressive function of the wild-type CIC protein, and is mainly mediated through the direct interaction of CIC-DUX4 with the acetyltransferase p300. In keeping with this, we show p300 to be essential for CDS tumor cell proliferation; additionally, we find its pharmacological inhibition to significantly impact tumor growth in vitro and in vivo. Taken together, our study elucidates the mechanisms underpinning CIC-DUX4-mediated transcriptional regulation.

oncology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to explore the epigenetic dependency and potential therapeutic targets of the CIC-DUX4 fusion protein in CIC-rearranged sarcomas (CDS). Specifically, the researchers conducted a genome-wide analysis of the DNA binding sites of CIC-DUX4 and its associated chromatin states, revealing how CIC-DUX4 acts as a potent transcriptional activator in these tumors. Additionally, they discovered that inhibiting the acetyltransferase p300 can hinder the proliferation of CDS tumor cells, providing a new direction for developing therapeutic strategies against CDS.

### Main Research Content

1. **DNA Binding Characteristics of CIC-DUX4**:
- The researchers analyzed the DNA binding sites of CIC-DUX4 in two established human CDS cell lines (CDS1 and CDS2) using ChIP-seq technology.
- The results showed that CIC-DUX4 primarily binds to DNA sequences containing TGAAT and GGAA motifs, and these binding sites are associated with active chromatin marks.

2. **Transcriptional Activation Function of CIC-DUX4**:
- The study found that CIC-DUX4 exhibits strong transcriptional activation at its binding sites, in contrast to the repressive function of its wild-type CIC protein.
- This transcriptional activation function is mainly achieved through the direct interaction of CIC-DUX4 with the acetyltransferase p300.

3. **Key Role of p300 in CDS**:
- Through genetic and pharmacological methods, the researchers confirmed the importance of p300 for the proliferation of CDS tumor cells.
- The p300 inhibitor A-485 significantly affected the growth of CDS tumors in both in vitro and in vivo experiments.

### Significance of the Study

This study not only enhances the understanding of the transcriptional regulatory mechanisms mediated by CIC-DUX4 but also proposes targeting p300 as a promising strategy for treating CDS. This is significant for developing new therapeutic approaches for this rare but aggressive soft tissue tumor.